Shaperon KRX:378800KOSDAQ
샤페론 · Korean news coverage and regulatory filings, organized.
Shaperon (샤페론) appeared in 0 Korean news articles and 1 DART filing over the past seven days. Coverage peaked on Nov 4 with 1 article. The most common catalyst was risk & warnings (1). It was most often mentioned alongside Vaxcell-Bio Therapeutics and HLB.
Filing signals Clinical trial filing 4 quarters of losses Delisting / halt risk Screener
Shaperon at a glance from DART filings
- Results trend
- Operating loss in each of the last 4 quarters; Q2 2026 operating loss of ₩3.1bn a loss again after the previous quarter.
- Ownership changes
- 3 5%-holder and insider ownership reports in the past 120 days (0 increases, 3 decreases).
Figures the company filed on DART, grouped by ATS View. Not a buy or sell call; see the cards below and the DART originals.
Shaperon today: up or down?
No sign-up, one tap a day. These numbers show what visitors think and are not investment advice.
Upcoming dates as filed
- Mar 31 Annual report filing deadlinein 134 days · period ending Dec 2026
Dates Shaperon stated in its DART filings. A conversion period opening does not mean new shares appear that day; bondholders must request conversion.
Shaperon quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q3 2026 check units | ₩4.6bn | – | −₩3.9bn | −₩4.0bn |
| Q2 2026 | ₩41m | – | −₩3.1bn | −₩3.7bn |
| Q1 2026 | ₩65m | +454.1% | −₩3.7bn | −₩3.5bn |
| Q4 2025 derived | ₩48m | – | −₩4.4bn | −₩4.4bn |
| Q3 2025 | ₩168m | – | −₩4.4bn | −₩4.2bn |
| Q2 2025 | ₩0m | -100.0% | −₩3.4bn | −₩3.4bn |
| Q1 2025 | ₩12m | – | −₩3.6bn | −₩3.5bn |
| Q4 2024 derived | ₩0m | -100.0% | −₩3.5bn | −₩3.4bn |
Q3 2026 Korean earnings rankings →
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Shaperon top stories 2 weeks, by number of outlets
- 1
- 2
Latest Shaperon news Korean headlines
-
MajorChaperon settles U.S. patent registration for 'nanobody' cancer therapy candidate
1 more on this story · 1 outlets
-
BIO Talk: L&C Bio presents fragmented tissue ECM reconstruction application, Chaperone and Autelic Bio
2 more on this story · 2 outlets
-
Chaperon launches bio beauty business in earnest based on anti-inflammatory and aging research
2 more on this story · 2 outlets
-
MajorChaperon gets international journal approval for theory paper explaining steroid efficacy limitations in atopic dermatitis
1 more on this story · 1 outlets
- Chaperon gets approval for paper on steroid long-term use limitations스페셜타임스 · Oct 13 15:10
-
Chaperon finds active drug and placebo code labeling error in Nugel; to verify actual components through court evaluation
1 more on this story · 1 outlets